Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
愛文思控股啓動了ADI-270相1臨床試驗的招募工作，針對轉移性/晚期透明/愛文思控股性腎細胞癌；首個可能應對實體瘤的伽馬三角體CAR T細胞療法即將進入臨床試驗；初步相1臨床...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025
Adicet 開放註冊用於轉移性/晚期透明細胞腎細胞癌的 ADI-270 1 期臨床試驗；首款有可能解決實體瘤的 Gamma Delta CAR t 細胞療法進入臨床試驗；1 期初步臨床數據預計將於 2025 年上半年公佈
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
首款有可能解決實體瘤的 gamma delta CAR t 細胞療法進入臨床試驗
Preliminary Phase 1 clinical data expected in the first half of 2025
第一階段的初步臨床數據預計將在2025年上半年公佈
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
Adicet Bio, Inc.（納斯達克股票代碼：ACET）是一家臨床階段的生物技術公司，該公司正在發現和開發針對自身免疫性疾病和癌症的異基因 gamma delta T 細胞療法，今天宣佈開始招募評估轉移性/晚期透明細胞腎細胞癌（cCRCC）患者的 ADI-270 的1期臨床試驗。
資訊熱榜
更新時間